Company profile: Q32 Bio
1.1 - Company Overview
Company description
- Provider of therapies for severe autoimmune and inflammatory diseases, including bempikibart (ADX-914), a fully human antiβIL-7 receptor alpha antagonist monoclonal antibody that blocks IL-7 and TSLP signaling to re-regulate adaptive immune function, and ADX-097, a humanized anti-C3d monoclonal antibody fusion protein aimed at restoring complement regulation via a tissue-targeted mechanism.
Products and services
- ADX-097: A humanized anti-C3d monoclonal antibody fusion protein engineered to restore complement regulation via a tissue-targeted mechanism for severe autoimmune and inflammatory disease management
- Bempikibart (ADX-914): A fully human antiβinterleukin-7 receptor alpha antagonist monoclonal antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling in autoimmune conditions
- Autoimmune Therapeutics Development: Develops immunology-focused treatments for patients with severe autoimmune and inflammatory diseases by emphasizing IL-7/TSLP pathway blockade and C3d-linked complement regulation
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Q32 Bio
Sudo Biosciences
HQ: United States
Website
- Description: Provider of TYK2 pseudokinase domainβtargeting medicines, including a brain-penetrant TYK2 inhibitor for multiple sclerosis and neurodegenerative diseases, and a topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Sudo Biosciences company profile β
Ventyx Biosciences
HQ: United States
Website
- Description: Provider of oral therapies for autoimmune, inflammatory and neurodegenerative disorders: VTX3232, a CNS-penetrant NLRP3 inhibitor for Parkinsonβs, obesity, Alzheimerβs and multiple sclerosis; VTX2735, an NLRP3 inhibitor for systemic inflammation, initially cardiovascular; VTX002, an S1P1R modulator for ulcerative colitis; and VTX958, a TYK2 inhibitor for Crohnβs disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Ventyx Biosciences company profile β
SARcode Bioscience
HQ: United States
Website
- Description: Provider of a novel class of small-molecule LFA-1 (CD11a/CD18; Ξ±LΞ²2) antagonists in development as topical agents to address significant unmet medical needs in ophthalmology, dermatology and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full SARcode Bioscience company profile β
Citryll
HQ: The Netherlands
Website
- Description: Provider of pharmaceutical drugs targeting Neutrophil Extracellular Traps (NETs) to treat autoimmune and inflammatory diseases such as SLE, RA, vasculitis, and IPF. Offers CIT-013, a therapeutic antibody; conducts NETosis inhibition research to reduce auto-antigen release and clear pro-inflammatory NETs; advances clinical development with first-in-human and planned Phase 2a trials in RA and hidradenitis suppurativa; and pursues collaboration opportunities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Citryll company profile β
Encycle Therapeutics
HQ: Canada
Website
- Description: Provider of a platform technology for rapid synthesis of drug-like macrocycles and membrane-permeable nacellins, which have potential to target intracellular protein-protein interactions largely intractable to small molecule and biologic modulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Encycle Therapeutics company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Q32 Bio
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Q32 Bio
2.2 - Growth funds investing in similar companies to Q32 Bio
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Q32 Bio
4.2 - Public trading comparable groups for Q32 Bio
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β